- Home
- CCIR vs HUMA Comparison
CCIR vs HUMA Comparison
Compare CCIR & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIR
- HUMA
- Stock Information
- Founded
- CCIR 2021
- HUMA 2004
- Country
- CCIR United States
- HUMA United States
- Employees
- CCIR N/A
- HUMA N/A
- Industry
- CCIR
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- CCIR
- HUMA Health Care
- Exchange
- CCIR NYSE
- HUMA Nasdaq
- Market Cap
- CCIR 340.2M
- HUMA 367.6M
- IPO Year
- CCIR 2024
- HUMA N/A
- Fundamental
- Price
- CCIR $10.94
- HUMA $2.32
- Analyst Decision
- CCIR
- HUMA Strong Buy
- Analyst Count
- CCIR 0
- HUMA 7
- Target Price
- CCIR N/A
- HUMA $13.00
- AVG Volume (30 Days)
- CCIR 483.1K
- HUMA 3.2M
- Earning Date
- CCIR 01-01-0001
- HUMA 08-12-2025
- Dividend Yield
- CCIR N/A
- HUMA N/A
- EPS Growth
- CCIR N/A
- HUMA N/A
- EPS
- CCIR 0.12
- HUMA N/A
- Revenue
- CCIR N/A
- HUMA $517,000.00
- Revenue This Year
- CCIR N/A
- HUMA N/A
- Revenue Next Year
- CCIR N/A
- HUMA $896.45
- P/E Ratio
- CCIR $88.86
- HUMA N/A
- Revenue Growth
- CCIR N/A
- HUMA N/A
- 52 Week Low
- CCIR $9.92
- HUMA $1.15
- 52 Week High
- CCIR $13.35
- HUMA $9.79
- Technical
- Relative Strength Index (RSI)
- CCIR N/A
- HUMA 50.18
- Support Level
- CCIR N/A
- HUMA $2.08
- Resistance Level
- CCIR N/A
- HUMA $2.40
- Average True Range (ATR)
- CCIR 0.00
- HUMA 0.14
- MACD
- CCIR 0.00
- HUMA -0.03
- Stochastic Oscillator
- CCIR 0.00
- HUMA 52.63
About CCIR COHEN CIRCLE ACQUISITION CORP I
Cohen Circle Acquisition Corp I is a blank check company.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.